Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.
A cell surface mechanism exists for the regulation of cellular responsiveness to pro-apoptotic stimuli in tumor cells. Expand
Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus1
- Jun Zhang, V. Roschke, +6 authors Tong Zhou
- The Journal of Immunology
- 1 January 2001
The results suggest that BLyS may be a useful marker for early activation of an autoimmune diathesis and likely plays a critical role in triggering activation of self-Ag-driven autoimmune B cells in human SLE and may provide an effective therapeutic target in systemic autoimmunity. Expand
Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer
- T. Harding, Li Long, +17 authors K. Baker
- Biology, Medicine
- Science Translational Medicine
- 27 March 2013
A soluble FGF receptor Fc fusion protein (FP-1039) is designed that binds tightly to all of the mitogenic FGF ligands, inhibits FGF-stimulated cell proliferation in vitro, blocks FGF– and vascular endothelial growth factor–induced angiogenesis in vivo, and inhibits in vivo growth of a broad range of tumor types. Expand
Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.
A fully human monoclonal antibody has been isolated that binds toBLyS with high affinity and neutralizes human BLyS bioactivity in vitro and in vivo. Expand
Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR
A new TNF-related ligand, designated human GITR ligand (hGITRL), and its human receptor, an ortholog of the recently discovered murine glucocorticoid-induced TNFR-related (mGITR) protein are identified. Expand
B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.
Dysregulation ofBLyS over extended periods of time is common in patients with SLE, and Neutralization of BLyS activity with an appropriate BLYS antagonist may be therapeutically beneficial. Expand
BLyS and APRIL Form Biologically Active Heterotrimers That Are Expressed in Patients with Systemic Immune-Based Rheumatic Diseases1
It is shown that APRIL and BLyS can form active heterotrimeric molecules when coexpressed and that circulatingheterotrimers are present in serum samples from patients with systemic immune-based rheumatic diseases. Expand
Tumor Necrosis Factor (TNF) Receptor Superfamily Member TACI Is a High Affinity Receptor for TNF Family Members APRIL and BLyS*
- Youmei Wu, D. Bressette, +18 authors K. Baker
- Chemistry, Medicine
- The Journal of Biological Chemistry
- 10 November 2000
It is concluded that TACI is a receptor for BLyS and APRIL and the implications for B-cell biology are discussed. Expand
Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus
APRIL may serve as a down modulator of serological and/or clinical autoimmunity in patients with SLE and its correlation with B lymphocyte stimulator (BLyS) expression, serum anti-dsDNA titres, and clinical disease activity is assessed. Expand
Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects.
- W. Halpern, P. Lappin, +4 authors K. Baker
- Toxicological sciences : an official journal of…
- 1 June 2006
Data confirm the specific pharmacologic activity of belimumab in reducing B lymphocytes in the cynomolgus monkey, and the favorable safety profile and lack of treatment-related infections also support continued clinical development ofBelimumab. Expand